Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$39.32

 0.95 (2.36%)

High$40.26
Low$39.01
Volume794,501
Market Cap$4,928,370,294

09/01/15  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation 08/17/15

Read more

Seattle Genetics Reports Second Quarter 2015 Financial Results 07/30/15

Read more

Events

Second Quarter 2015 Financial Results Conference Call07/30/15 4:30 p.m. ETView eventUBS Global Healthcare Conference05/19/15 2:00 p.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources